Health Services Deals Remain Resilient Despite Slower Volume, PwC Reports

The health services sector has seen a notable shift in deal dynamics, according to the midyear outlook report from PwC. While the number of deals decreased in the first half of 2026, the overall deal value remained resilient, driven by large transactions and a strategic repricing of risk. This trend highlights how investors are adapting to market pressures, including geopolitical uncertainties, reimbursement challenges, and the ongoing "SaaS apocalypse."

Dan Farrell, Health Services Deals Leader at PwC U.S., noted that while fewer deals are getting done, the ones that do are larger and more conviction-backed. "We're not seeing a retreat from healthcare deals; we're seeing a repricing of risk," he said. "Capital remains available, but investors are demanding more proof points before committing."

In the first quarter of 2026, there were 300 health services deals, down from 308 in Q4 2025 and 324 in Q3 2025. However, deal value in Q1 hit $18 billion and reached $10 billion by the end of May 2026. In contrast, Q4 2025 saw a significant jump to $29 billion from $8 billion in both Q3 and Q2 of the previous year.

Market Pressures Drive Strategic Focus

The health services market is grappling with several challenges, including skyrocketing costs, labor shortages, and compressed margins. These factors are pushing investors and dealmakers to be more selective, focusing on assets with strong fundamentals and stable reimbursement models. The physician medical group sector, for instance, captured a record 46% of first-quarter deal volume, indicating that buyers are still interested but are setting higher standards for investment.

Farrell emphasized that the margin squeeze is rewriting the playbook. "Buyers are prioritizing assets with clear value propositions, strong financials, and stable reimbursement," he explained. This strategic focus is evident in the increasing number of large transactions, which are driving overall deal value despite a decline in volume.

The trend toward larger, more strategic deals is also reflected in other sectors within health services. For example, AI and advanced analytics are gaining traction as investors look for technologies that can optimize costs and improve patient outcomes. According to Fierce Biotech, the integration of AI into healthcare processes is becoming increasingly important, particularly in areas like clinical research and operational efficiency.

Investment Implications

The evolving landscape of health services deals has several implications for investors and industry stakeholders. First, the emphasis on larger, more strategic transactions suggests that smaller, less robust assets may struggle to attract investment. This could lead to consolidation within certain segments of the market, as larger players seek to build comprehensive portfolios.

Second, the demand for strong proof points and stable reimbursement models will likely drive innovation in areas such as AI and data analytics. These technologies can help mitigate risks and improve financial performance, making them attractive targets for investment.

Finally, the ongoing pressures in the health services market-such as labor shortages and rising costs-will continue to shape deal dynamics. Investors will need to remain adaptable and focused on assets that can deliver sustainable value in a challenging environment.

While the number of health services deals has dipped, the overall value remains strong due to larger, more strategic transactions. Investors are setting higher standards for investment, focusing on assets with robust fundamentals and stable reimbursement models. This shift underscores the importance of adaptability and innovation in navigating the evolving healthcare landscape.